XTL Biopharmaceuticals Files 2024 Annual Report
Ticker: XTLB · Form: 20-F · Filed: Apr 30, 2025 · CIK: 1023549
| Field | Detail |
|---|---|
| Company | Xtl Biopharmaceuticals Ltd (XTLB) |
| Form Type | 20-F |
| Filed Date | Apr 30, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: annual-report, 20-f, pharmaceuticals
TL;DR
XTL Bio filed its 2024 20-F. Check financials.
AI Summary
XTL Biopharmaceuticals Ltd. filed its annual report on Form 20-F for the fiscal year ended December 31, 2024. The company, incorporated in Israel, is listed under the Pharmaceutical Preparations SIC code. Its principal executive offices are located at 26 Ben-Gurion St., Ramat Gan, Israel.
Why It Matters
This filing provides investors with a comprehensive overview of XTL Biopharmaceuticals' financial performance and business operations for the past fiscal year, crucial for investment decisions.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, XTL Biopharmaceuticals is subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Players & Entities
- XTL BIOPHARMACEUTICALS LTD (company) — Registrant
- 2024 (date) — Fiscal year end
- December 31 (date) — Fiscal year end
- Israel (location) — Jurisdiction of incorporation
- 26 Ben-Gurion St. (address) — Principal executive offices
- Ramat Gan (location) — Principal executive offices
- Noam Band (person) — Chief Executive Officer
FAQ
What is the primary business of XTL Biopharmaceuticals Ltd.?
XTL Biopharmaceuticals Ltd. is classified under the Pharmaceutical Preparations industry (SIC code 2834).
In which jurisdiction was XTL Biopharmaceuticals Ltd. incorporated?
XTL Biopharmaceuticals Ltd. was incorporated in Israel.
What is the filing date of this 20-F report?
This 20-F report was filed as of April 30, 2025.
What period does this annual report cover?
This annual report covers the fiscal year ended December 31, 2024.
Who is listed as the Chief Executive Officer of XTL Biopharmaceuticals Ltd.?
Noam Band is listed as the Chief Executive Officer.
Filing Details
This Form 20-F (Form 20-F) was filed with the SEC on April 30, 2025 by Noam Band regarding XTL BIOPHARMACEUTICALS LTD (XTLB).